94-24-6 Usage
Uses
Different sources of media describe the Uses of 94-24-6 differently. You can refer to the following data:
1. Tetracaine is used in assessing the potential for drug-nanoparticle surface interactions to improve drug penetration into the skin.
2. analgesic
3. Tetracaine has been used as an anesthetic and to lower the glucose synthesis in upper small intestinal infusions. It has also been used to inhibit ryanodine receptors (RyRs) in rats.
4. Topical ophthalmic anesthetic; used for spinal anesthesia
5. Tetracaine, also known as amethocaine, is the most potent and lipidsoluble
ester local anaesthetic and has significant potential for toxicity if
used systemically. It is commonly used as a 4% gel for topical application to
decrease the pain from venous puncture or cannulation.
Description
Tetracaine is a local anesthetic or numbing medicine that is used to numb the throat, eyes, or nose. Normally, the drug is administered before starting a surgery to decrease pain from the procedure. Tetracaine is applied to the eyes 30 minutes before the start of an intravenous and its effects can last up to 15 minutes.
Mechanism of Action
Tetracaine acts by blocking the nerve systems. It does this by blocking the sodium ion channels needed for the conduction and initiation of neural impulses, thereby affecting the local anesthesia. Tetracaine acts by altering the function of calcium release channels that controls the release of calcium frim intracellular cells.
Precautions
No studies have revealed whether the medicine can affect an unborn child; however, it is important to inform the doctor if pregnant while using it.
Informing the doctor is paramount if breastfeeding a baby, as no known research has illustrated whether tetracaine can pass into breast milk or harm a nursing baby.
To make tetracaine safe, it is important to inform the doctor if one has a history of spinal or brain injury, heart diseases, eye problems, a blood vessel disorder, open sores, skin injury in the area where the medicine will be applied.
Tetracaine should never be orally taken since it is typically designed for use on the skin only. If the medicine gets in the mouth, nose, vagina, or rectum, rinse with water.
Application
Tetracaine topical (for the skin) is used to numb various body parts before a surgical procedure or a medical test. Conversely, tetracaine ophthalmic drops are used as local anesthetic for the eyes.
Dosage
Always follow all direction on the prescription label. Do not use the medicine in smaller or larger amounts or for longer than recommended.
Side Effects
Seek emergency medical advice in case of any of the following allergic reactions: difficult breathing, hives, swelling of the throat, tongue, lips, or face. Stop using the drug and call the physician if one has severe burning, swelling, stinging, or other irritation of the treated skin. Other alarming symptoms include eye watering, irritation, and increased sensitivity to light.
Common side effects include burning, stinging, or itching at the point of application of the medicine; numbness in places where tetracaine has been accidentally applied or skin redness or tenderness.
Nonclinical Toxicology
Studies conducted to reveal the genotoxicity of tetracaine have not indicated its mutagenesis, carcinogenicity, or impairment of fertility.
Chemical Properties
White or light-yellow, waxy solid. Very slightly soluble in water; soluble in
alcohol, ether, benzene, chloroform.
Definition
ChEBI: A benzoate ester in which 4-N-butylbenzoic acid and 2-(dimethylamino)ethanol have combined to form the ester bond; a local ester anaesthetic (ester caine) used for surface and spinal anaesthesia.
Biological Functions
Tetracaine hydrochloride (Pontocaine) is an ester of
PABA that is an effective topical local anesthetic agent and also is quite commonly used for spinal (subarachnoid)
anesthesia. Epinephrine is frequently added to
prolong the anesthesia.Tetracaine is considerably more
potent and more toxic than procaine and cocaine. It
has approximately a 5-minute onset and 2 to 3 hours of
action.
General Description
Tetracaine was developed to address the low potency andshort duration of action of procaine and chloroprocaine. The addition of the butyl side chain on the para nitrogen increasesthe lipid solubility of the drug and enhances the topical potencyof tetracaine. The plasma half-life is 120 to 150 seconds.Topically applied tetracaine to unbroken skin requires 30 to 45minutes to confer topical anesthesia. Tetracaine 4% gel is superiorthan eutectic mixture with lidocaine (EMLA) (an emulsionof lidocaine and prilocaine) in preventing pain associatedwith needle procedures in children. Tetracaine metabolism issimilar to procaine ester metabolism yielding parabutylaminobenzoicacid and dimethylaminoethanol and conjugatesexcreted in the urine. The pKa of the dimethylated nitrogen is8.4 and tetracaine is formulated as a hydrochloride salt with apH of 3.5 to 6.0. The increased absorption from topical siteshas resulted in reported toxicity. Overdoses of tetracaine mayproduce central nervous system (CNS) toxicity and seizure activitywith fatalities from circulatory depression reported.No selective cardiac toxicity is seen with tetracaine althoughhypotension has been reported. Tetracaine is employed for infiltrationanesthesia, spinal anesthesia, or topical use.
Biochem/physiol Actions
Tetracaine also refers as 4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester interfere with calcium movement in muscle and non-muscle cells and can inhibit potassium-induced as well as caffeine-induced shortening of outer hair cells (OHC′s). But, the product can′t inhibit electrically-induced shortening of OHC′s.The product can also stimulate caspase activation and inhibits pro-survival signalling pathways which in turn induce human renal cell apoptosis.
Veterinary Drugs and Treatments
Tetracaine is more irritating than proparacaine but is sometimes
used in veterinary medicine. It is indicated to produce local anesthesia
of short duration for ophthalmic procedures including measurement
of intraocular pressure (tonometry), removal of foreign
bodies and sutures, and conjunctival and corneal scraping in diagnosis
and gonioscopy. Tetracaine is also indicated to produce local
anesthesia prior to surgical procedures in humans such as cataract
extraction and pterygium excision, usually as an adjunct to locally
injected anesthetics. Ophthalmic solutions used for intraocular
procedures should be preservative-free. Preservatives may cause
damage to the corneal epithelium if a significant quantity of solution
enters the eye through the incision.
Check Digit Verification of cas no
The CAS Registry Mumber 94-24-6 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 9 and 4 respectively; the second part has 2 digits, 2 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 94-24:
(4*9)+(3*4)+(2*2)+(1*4)=56
56 % 10 = 6
So 94-24-6 is a valid CAS Registry Number.
InChI:InChI=1/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H3
94-24-6Relevant articles and documents
A new method of dicaine synthesis from p-nitrobenzoic acid ethylate
Abdullaev
, p. 28 - 31 (2002)
-
Preparation method of tetracaine hydrochloride
-
Paragraph 0014, (2017/04/22)
The invention relates to the technical field of preparation method of tetracaine hydrochloride. The preparation method comprises the preparation steps: carrying out a reaction of p-nitrobenzoyl chloride (2) and 2-dimethylamino-1-ethanol (3) to generate p-nitrobenzoic acid-2-dimethylamino ethyl (4), reducing the compound (3) to obtain p-aminobenzoic acid-2-dimethylamino ethyl (4), generating pontocaine (7) from a compound (5) and 1-bromobutane (6) under alkaline conditions, and finally carrying out a reaction of the pontocaine (7) with HCl to generate tetracaine hydrochloride (1).
Microcapsules, method of making and their use
-
, (2008/06/13)
The invention relates to microcapsules to a microcapsule with a mean size from a fraction of micrometer to 1000 micrometers having a biodegradable membrane encapsulating a gas core. The membrane comprising one or more biodegradable water insoluble lipids or mixtures thereof and optionally mixtures of the lipids with up to 75% by weight of biodegradable polymers encapsulates the core which is filled with air or a gas. Microcapsules disclosed, may be non-coalescent, dry and instantly dispersible, when in suspension in a physiologically acceptable carrier are useful as delivery vehicles for therapeutically active agents and/or as contrast agents for echographic imaging of organs of human or animal body. The microcapsules of the invention are made by a method in which a water-in-oil emulsion is made from an organic solution comprising dissolved a mono-, di-, triglyceride preferably tripalmitin or tristearin and optionally therapeutically active substance and an aqueous solution containing a surfactant, optionally evaporating part of the solvent, adding a redispersing agent and freeze drying the mixture. The freeze dried mixture is then redispersed in an aqueous carrier to separate microcapsules from debris and the semi-spherical or spherical microcapsules are dried.
